# exosomes
Latest news and articles about exosomes
Total: 4 articles found
China’s 3·15 Consumer Gala Lifts the Lid on Food, Health and AI Fraud — From Bleached Chicken to ‘GEO’ Manipulation
China’s 2026 3·15 consumer rights gala exposed systemic consumer harms across food processing, cosmetic medicine, mobility rentals, AI manipulation and financial scams. State media named firms and supply chains responsible for illegal bleaching of poultry, unproven exosome treatments, dangerously non‑compliant e‑bikes, and GEO services that deliberately bias AI models through mass content seeding.
CCTV’s 3·15 Exposé Triggers Overnight Crackdown on Food, Health and Consumer Scams Across Chinese Cities
China’s state broadcaster top consumer-rights show exposed multiple consumer-safety and fraud allegations, prompting the national market regulator and municipal authorities to launch immediate joint investigations. Authorities have ordered suspensions, seized products and opened cases across food processing, medical‑health products, online marketing and e-bike rentals, signalling intensified enforcement and higher compliance risk for firms operating in these sectors.
China’s 3·15 Consumer Gala Unmasks Food Bleaching, Fake ‘Exosome’ Cures and AI ‘Poisoning’ Schemes
China’s 2026 3·15 consumer‑rights broadcast exposed a range of consumer harms — from chemically bleached snack foods and unlicensed anti‑ageing “exosome” products to pseudo‑medical height clinics, private‑domain price gouging, e‑bike safety violations, AI‑manipulation services and stock recommendation scams. The programme named dozens of companies, including units linked to listed firms, prompting swift local regulatory action and highlighting systemic gaps in compliance, platform oversight and consumer protection.
CCTV Spotlight Sinks Credibility of Zhengzhou Biotech as Multiple Patents Rejected
CCTV’s consumer‑rights programme named Zhengzhou Yuanchuang Gene in a probe of overhyped exosome products, and public records show several of the company’s patent applications have been rejected. The development highlights the tension between genuine exosome research and a market of unproven claims, and signals heightened regulatory and reputational risks for small biotech firms in China.